Show simple item record

dc.contributor.authorEisen, DP
dc.contributor.authorMoore, EM
dc.contributor.authorLeder, K
dc.contributor.authorLockery, J
dc.contributor.authorMcBryde, ES
dc.contributor.authorMcNeil, JJ
dc.contributor.authorPilcher, D
dc.contributor.authorWolfe, R
dc.contributor.authorWoods, RL
dc.date.accessioned2020-12-21T01:36:08Z
dc.date.available2020-12-21T01:36:08Z
dc.date.issued2017-01-01
dc.identifierpii: bmjopen-2016-013636
dc.identifier.citationEisen, D. P., Moore, E. M., Leder, K., Lockery, J., McBryde, E. S., McNeil, J. J., Pilcher, D., Wolfe, R. & Woods, R. L. (2017). AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol. BMJ OPEN, 7 (1), https://doi.org/10.1136/bmjopen-2016-013636.
dc.identifier.issn2044-6055
dc.identifier.urihttp://hdl.handle.net/11343/256578
dc.description.abstractINTRODUCTION: Sepsis is a leading global cause of morbidity and mortality, and is more common at the extremes of age. Moreover, the cost of in-hospital care for elderly patients with sepsis is significant. There are indications from experimental and observational studies that aspirin may reduce inflammation associated with infection. This paper describes the rationale and design of the AspiriN To Inhibit SEPSIS (ANTISEPSIS) trial, a substudy of ASPirin in Reducing Events in the Elderly (ASPREE). ANTISEPSIS primarily aims to determine whether low-dose aspirin reduces sepsis-related deaths in older people. Additionally, it will assess whether low-dose aspirin reduces sepsis-related hospitalisations and sepsis-related Intensive Care Unit (ICU) admissions. METHODS AND ANALYSIS: ASPREE is a double-blinded, randomised, placebo-controlled primary prevention trial that will determine whether daily low-dose aspirin extends disability-free longevity in 19 000 healthy older people recruited in Australia and the USA. The ANTISEPSIS substudy involves additional ASPREE trial data collection to assess the impact of daily low-dose aspirin on sepsis-related events in the 16 703 ASPREE participants aged 70 years and over, recruited in Australia. The intervention is a daily 100 mg dose of enteric-coated aspirin versus matching placebo, with 1:1 randomisation. The primary outcome for the ANTISEPSIS substudy is the incidence of sepsis-related death in eligible patients. The incidence of sepsis-related hospital and ICU admissions are secondary outcomes. ANTISEPSIS is to be conducted between 2012 and 2018. DISCUSSION: This substudy will determine whether aspirin, an inexpensive and accessible therapy, safely reduces sepsis-related deaths and hospitalisations in older Australians. If shown to be the case, this would have profound effects on the health of older Australians. TRIAL REGISTRATION NUMBER: Pre-results, ACTRN12613000349741.
dc.languageEnglish
dc.publisherBMJ PUBLISHING GROUP
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleAspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol
dc.typeJournal Article
dc.identifier.doi10.1136/bmjopen-2016-013636
melbourne.affiliation.departmentDoherty Institute
melbourne.affiliation.departmentMedicine (RMH)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleBMJ Open
melbourne.source.volume7
melbourne.source.issue1
dc.rights.licenseCC BY-NC
melbourne.elementsid1224536
melbourne.contributor.authorMcBryde, Emma
melbourne.contributor.authorEisen, Damon
melbourne.contributor.authorLeder, Karin
dc.identifier.eissn2044-6055
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record